• The program, which is exclusively licensed to BMS, marks the third ADC candidate utilizing Tubulis’ Tubutecan technology to reach the clinical trial stage. 

MUNICH, GERMANY, May 20, 2025 – Tubulis announced today that the first program resulting from its strategic collaboration with BMS has entered clinical trials, representing a significant milestone in their ongoing partnership focused on developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. The agreement, established in 2023, combines the oncology and clinical development expertise of Bristol Myers Squibb (BMS) with Tubulis’ distinctive approach to ADC design to create highly differentiated ADCs for treating solid tumors.

“Within two years, this collaboration has successfully advanced a promising ADC candidate into clinical development, and we are strongly committed to this valuable partnership,” stated Dominik Schumacher, PhD, CEO and co-founder of Tubulis. “Having advanced three Tubutecan-based ADC candidates into the clinic within just 12 months, including our wholly owned programs TUB-030 and TUB-040, we continue to demonstrate the versatility and potential of our technologies in creating more effective cancer therapies.”

Tubulis’ Tubutecan technology combines the company’s P5 conjugation system with an exatecan payload, allowing for the development of stable, targeted ADCs designed to deliver the topoisomerase-1 inhibitor directly to the tumor while minimizing systemic toxicity. The resulting ADC candidates aim to overcome the limitations of earlier ADCs, providing new therapeutic options for patients with a range of aggressive and difficult-to-treat solid tumors.

According to the original collaboration agreement, Bristol Myers Squibb has exclusive rights to develop and commercialize specific ADCs using Tubulis’ Tubutecan platform. Tubulis is eligible for development, regulatory, and commercial milestone payments, as well as royalties on marketed products resulting from the collaboration.

About Tubulis
Tubulis creates uniquely tailored antibody-drug conjugates with enhanced biophysical properties, demonstrating sustained on-tumor delivery and long-lasting anti-tumor activity in preclinical studies. The company’s two leading programs, TUB-040 (targeting NaPi2b) and TUB-030 (directed against 5T4), are currently being evaluated in clinical trials for solid tumor indications with significant unmet needs. Tubulis intends to strengthen its leadership position by continuously innovating in all aspects of ADC design, utilizing its proprietary platform technologies to broaden the therapeutic potential of this drug class for its pipeline, partners, and patients. Visit or follow us on .

Contacts

For Tubulis
Dominik Schumacher, CEO & Co-founder
Phone: +49 (0) 175 800 5594
Email:

Media Requests for Tubulis
Trophic Communications
Stephanie May, PhD
Phone: +49 (0) 171 185 56 82
Email:

Attachment

“`